These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3813296)

  • 21. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.
    Charreire J; Karsenty G; Bouchard P; Schaison G
    Clin Exp Immunol; 1984 Sep; 57(3):633-8. PubMed ID: 6147216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of variability in Graves' disease: stimulatory TSH-receptor antibodies bind to the TSH-receptor in a continued, non-pulsatile and non-chaotic fashion.
    Schuppert F; Diegelmann B; Geest T; Wagner TO; von zur Mühlen A
    Chronobiologia; 1994; 21(1-2):21-32. PubMed ID: 7924634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production, isolation, and characterization of rabbit anti-idiotypic antibodies directed against human antithyrotrophin receptor antibodies.
    Baker JR; Lukes YG; Burman KD
    J Clin Invest; 1984 Aug; 74(2):488-95. PubMed ID: 6086714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-triiodothyronine antibodies in Basedow's disease treated with carbimazole].
    Heshmati HM; Izembart M; Turpin G; Vallée G
    Presse Med; 1989 Dec 16-23; 18(42):2066. PubMed ID: 2532348
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical implications of a new TSH receptor antibody assay (DYNOtest TRAKhuman) in autoimmune thyroid diseases].
    Meller J; Schreivogel I; Bergmann A; Morgenthaler N; Hüfner M; Becker W
    Nuklearmedizin; 2000; 39(1):14-8. PubMed ID: 10726252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of autoimmunity in Graves' disease before and after treatment with carbimazole.
    Zosin I; Arcan P; Lungu G; Cotoi A; Opreanu R
    Endocrinologie; 1988; 26(1):49-53. PubMed ID: 3260398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relapse in Basedow's disease after treatment with synthetic antithyroid drugs. Prognostic value of analysis of the HLA system].
    Allannic H; Fauchet R; Lorcy Y; Gueguen M; Le Guerrier AM; Genetet B
    Presse Med; 1983 Dec; 12(44):2797-800. PubMed ID: 6228849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [99mTc uptake and TSH receptor autoantibodies--comparative study in Basedow's disease and other thyroid diseases].
    Baum RP; Happ J; Maul FD; Standke R; Hör G
    Nuklearmedizin; 1985 Jun; 24(3):141-5. PubMed ID: 2997753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of therapy duration and low and highly dosed thiamazole treatment in Basedow's-Graves' disease.
    Meng W; Meng S; Männchen E; Hampel R; Kirsch G; Dannenberg J; Krabbe S
    Exp Clin Endocrinol; 1991 May; 97(2-3):257-60. PubMed ID: 1915642
    [No Abstract]   [Full Text] [Related]  

  • 30. Late recurrence of Graves' disease.
    Lewis NP
    Br J Clin Pract; 1989 Feb; 43(2):82. PubMed ID: 2803906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of radioactive iodine treatment on TSH receptor antibodies in Basedow's disease].
    Heshmati HM; Dagousset F; Izembart M; Clerc J
    Presse Med; 1992 Feb; 21(6):268. PubMed ID: 1532644
    [No Abstract]   [Full Text] [Related]  

  • 32. [New thoughts on Basedow's disease--special reference to TSH receptor].
    Onaya T
    Nihon Naika Gakkai Zasshi; 1995 Mar; 84(3):403-6. PubMed ID: 7751778
    [No Abstract]   [Full Text] [Related]  

  • 33. [Unclear weight loss. Basedow's disease resp. Graves' disease].
    Stettler LB
    Praxis (Bern 1994); 2004 Oct; 93(42):1743-4. PubMed ID: 15529962
    [No Abstract]   [Full Text] [Related]  

  • 34. Insulin autoantibodies in Graves' disease--before and after carbimazole therapy.
    Armitage M; Franklyn J; Scott-Morgan L; Parr J; Borsey DQ; Sheppard M; Wilkin TJ
    Diabetes Res Clin Pract; 1990 Mar; 8(3):169-76. PubMed ID: 2340791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-thyrotropin-receptor antibodies in Basedow's disease. Correlations with in vitro and in vivo parameters].
    Heshmati HM; Izembart M; Chevalier A; Vallée G
    Presse Med; 1986 Dec; 15(45):2253-4. PubMed ID: 2949260
    [No Abstract]   [Full Text] [Related]  

  • 36. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease.
    Wilson R; McKillop JH; Henderson N; Pearson DW; Thomson JA
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):151-6. PubMed ID: 3491692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Basedow's disease and interferon for hepatitis C. Recurrence as Basedow's ophthalmopathy after interferon reintroduction].
    Huet D; Entremont A; Hautecouverture M
    Presse Med; 2000 Jan; 29(2):82. PubMed ID: 10682035
    [No Abstract]   [Full Text] [Related]  

  • 38. Insulin autoantibodies before and after carbimazole therapy in Asian Indian patients with Graves' disease.
    Goswami R; Jayasuryan N; Jaleel A; Tandon N; Kochupillai N
    Diabetes Res Clin Pract; 1998 Jun; 40(3):201-6. PubMed ID: 9716924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specificity of the immunosuppressive action of carbimazole in Graves's disease.
    McGregor AM; Rees Smith B; Hall R; Collins PN; Franco Bottazzo G; Petersen MM
    Br Med J (Clin Res Ed); 1982 Jun; 284(6331):1750-1. PubMed ID: 6282385
    [No Abstract]   [Full Text] [Related]  

  • 40. [Increased urinary excretion of neopterin in patients with Graves-Basedow disease].
    Schreiber V; Tomsová Z; Límanová Z; Jůzová Z
    Cas Lek Cesk; 1989 Jul; 128(28):883-4. PubMed ID: 2790883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.